Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): In a method for selectively enriching/removing a serum albumin from a mixture of other compounds by contacting said mixture with a ligand (= X), the improvement comprising said ligand

- a) having affinity for and enabling binding of the serum albumin and
- b) being attached via a spacer (= B) to a base matrix (= M') insoluble in the aqueous media used, the matrix with the attached ligand being represented by M-B-X

where M is the matrix, B is the spacer and X the affinity ligand, with the provision that M may contain further groups X linked via a spacer,

wherein said ligand X has been selected among serum albumin-binding structures complying with the formulae

$$R_2$$
 R_3
 R_4

in which

a) the free valence bind to the spacer B;

b) R₁₋₄ are selected from hydrogen, electron withdrawing groups, such as

halogens and lower alkyl groups (C1-10) that-possibly are substituted with

electron withdrawing groups, such as halogens;

e) Z and Y are selected among oxygen, sulphur or nitrogen, with the

provision that the nitrogen may earry a positive charge,

wherein contact between the mixture and the media M-B-X is done in an aqueous

media having a pH at which the -B-X carries a positive charge.

Claim 2 (cancelled)

Claim 3 (currently amended): The method of claim 1, wherein at least one of R₁₋₄ exhibit

an electron withdrawing group, preferably selected among halogens such as fluorine.

Claim 4 (previously presented): The method of claim 1, wherein the spacer has a sulphur

atom next to X.

Claim 5 (previously presented): The method of claim 1, wherein Z and Y are nitrogens,

one of which binding to a hydrogen and the ligand structure being charged depending of

pН.

Page 3 of 7

Appl. No. 09/869,023 Amendment dated June 26, 2006 Reply to Examiner's Answer of May 5, 2006

Claim 6 (previously presented): The method of claim 1, wherein said mixture derives

from a host in which said serum albumin is human scrum albumin.

Claim 7 (previously presented): The method of claim 1, wherein said ligand is attached

covalently to said matrix.

Claim 8 (previously presented): The method of claim 1, wherein after the adsorption step

said serum albumin is eluted from said affinity adsorbent and if necessary further

processed.

Claims 9 - 10 (cancelled)